| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.9561M |
| P356 | DOI | 10.1073/PNAS.160105897 |
| P932 | PMC publication ID | 16904 |
| P698 | PubMed publication ID | 10920191 |
| P5875 | ResearchGate publication ID | 12400151 |
| P50 | author | Raphael Mechoulam | Q903973 |
| P2093 | author name string | M Feldmann | |
| A M Malfait | |||
| R Gallily | |||
| A S Malik | |||
| E Andreakos | |||
| P F Sumariwalla | |||
| P2860 | cites work | Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers | Q72649288 |
| Toxicity of short-term administration of cannabinoids to rhesus monkeys | Q72892604 | ||
| DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition | Q73705668 | ||
| Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound | Q73979439 | ||
| Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | Q24685540 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| Determination and characterization of a cannabinoid receptor in rat brain | Q29618888 | ||
| Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis | Q33557750 | ||
| Towards cannabinoid drugs--revisited. | Q33906007 | ||
| Marihuana Chemistry | Q34222495 | ||
| Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4 | Q36350833 | ||
| Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice | Q37147228 | ||
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis | Q37253521 | ||
| Structure-activity relationships in cannabinoids | Q39504398 | ||
| Constituents of Cannabis sativa L. XVII. A review of the natural constituents | Q40284493 | ||
| Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells | Q40987444 | ||
| Cannabis: pharmacology and toxicology in animals and humans | Q41278775 | ||
| delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages | Q41337353 | ||
| Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis | Q41430466 | ||
| Hashish. I. The structure of cannabidiol | Q42239859 | ||
| Comparative receptor binding analyses of cannabinoid agonists and antagonists. | Q42543732 | ||
| Tetrahydrocannabinol inhibition of macrophage nitric oxide production | Q42554637 | ||
| Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure | Q42833162 | ||
| Biphasic effects of anandamide | Q43332781 | ||
| Controlled clinical trial of cannabidiol in Huntington's disease | Q45293556 | ||
| Cannabinoid receptors and immunity | Q48029970 | ||
| Use of MTT colorimetric assay to measure cell activation. | Q50906624 | ||
| A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. | Q53438021 | ||
| Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo | Q55049959 | ||
| Isolation and structure of .DELTA.+- tetrahydrocannabinol and other neutral cannabinoids from hashish | Q57320417 | ||
| Homologous type II collagen induces chronic and progressive arthritis in mice | Q57352747 | ||
| Immunisation against heterologous type II collagen induces arthritis in mice | Q59053172 | ||
| Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis | Q60461800 | ||
| Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis | Q60461810 | ||
| Analgesic and antiinflammatory activity of constituents of Cannabis sativa L | Q67930413 | ||
| Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity | Q68091387 | ||
| Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro | Q68280138 | ||
| Marijuana and immunity: tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis | Q68456760 | ||
| Mycoplasma capricolum membranes induce tumor necrosis factor alpha by a mechanism different from that of lipopolysaccharide | Q68748299 | ||
| Chronic administration of cannabidiol to healthy volunteers and epileptic patients | Q71314177 | ||
| Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis | Q71425894 | ||
| Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins | Q72194401 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabidiol | Q422917 |
| cannabinoids | Q422936 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 9561-9566 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis | |
| P478 | volume | 97 |
| Q90263162 | A Cross-Sectional Study of Cannabidiol Users |
| Q51731195 | A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains. |
| Q92701738 | A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects |
| Q35865445 | A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis |
| Q44830885 | A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'. |
| Q30670447 | A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis |
| Q34113027 | Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion |
| Q36271120 | Analysing the effect of novel therapies on cytokine expression in experimental arthritis |
| Q90477516 | Anti-Inflammatory, Antioxidative, and Hepatoprotective Effects of Trans Δ9-Tetrahydrocannabinol/Sesame Oil on Adjuvant-Induced Arthritis in Rats |
| Q90370300 | Antinociceptive and Immune Effects of Delta-9-tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain |
| Q34232627 | Anxiogenic-like effects of chronic cannabidiol administration in rats |
| Q46990183 | Arthritis and cannabinoids: HU-210 and Win-55,212-2 prevent IL-1alpha-induced matrix degradation in bovine articular chondrocytes in-vitro |
| Q52615780 | Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. |
| Q42689224 | Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis |
| Q57021776 | Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice |
| Q36416335 | Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists |
| Q56168914 | Biosynthesis of cannabinoids |
| Q36785192 | Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice |
| Q51316104 | Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. |
| Q98891256 | Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts |
| Q30497010 | Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development |
| Q91045445 | Cannabidiol Regulates Gene Expression in Encephalitogenic T cells Using Histone Methylation and noncoding RNA during Experimental Autoimmune Encephalomyelitis |
| Q33690796 | Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation |
| Q34627188 | Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease |
| Q36501954 | Cannabidiol arrests onset of autoimmune diabetes in NOD mice |
| Q99238683 | Cannabidiol as a Novel Therapeutic for Immune Modulation |
| Q34898890 | Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress |
| Q42181862 | Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury |
| Q34519365 | Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy |
| Q37192723 | Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death |
| Q37729156 | Cannabidiol attenuates delayed-type hypersensitivity reactions via suppressing T-cell and macrophage reactivity |
| Q36431803 | Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption |
| Q38347321 | Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis |
| Q38012845 | Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? |
| Q34672113 | Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice |
| Q34657897 | Cannabidiol in humans-the quest for therapeutic targets |
| Q35193309 | Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice |
| Q28298326 | Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors |
| Q37217043 | Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation |
| Q55041970 | Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. |
| Q42811858 | Cannabidiol promotes browning in 3T3-L1 adipocytes |
| Q34851941 | Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death |
| Q33959167 | Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy |
| Q48470514 | Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. |
| Q36176491 | Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus |
| Q46985556 | Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury |
| Q24645241 | Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice |
| Q83997591 | Cannabidiol-induced apoptosis in murine microglial cells through lipid raft |
| Q93199827 | Cannabidiol: A Brief Review of Its Therapeutic and Pharmacologic Efficacy in the Management of Joint Disease |
| Q34157378 | Cannabidiol: an overview of some pharmacological aspects |
| Q37285921 | Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action |
| Q57148532 | Cannabinoid Delivery Systems for Pain and Inflammation Treatment |
| Q37752096 | Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas |
| Q34583231 | Cannabinoid control of neuroinflammation related to multiple sclerosis |
| Q35594830 | Cannabinoid receptors and endocannabinoids: evidence for new players. |
| Q35897353 | Cannabinoid signaling in glial cells |
| Q36111923 | Cannabinoid-based drugs as anti-inflammatory therapeutics |
| Q37015392 | Cannabinoid-induced immune suppression and modulation of antigen-presenting cells |
| Q33581824 | Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells |
| Q34786842 | Cannabinoids and cell fate. |
| Q35046205 | Cannabinoids and neuroinflammation |
| Q33688381 | Cannabinoids as novel anti-inflammatory drugs |
| Q39119286 | Cannabinoids decrease the th17 inflammatory autoimmune phenotype |
| Q89047296 | Cannabinoids for the treatment of rheumatic diseases - where do we stand? |
| Q47643955 | Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? |
| Q41687142 | Cannabinoids in the management of difficult to treat pain |
| Q38005189 | Cannabinoids: novel therapies for arthritis? |
| Q37010970 | Cannabinoids:their role in pain and palliation |
| Q37143569 | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation |
| Q89510317 | Cannabis Sativa Revisited-Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis |
| Q89526821 | Cannabis and Cannabinoids in the Treatment of Rheumatic Diseases |
| Q30040327 | Cannabis and Cannabis Extracts |
| Q44255260 | Cannabis is more than simply delta(9)-tetrahydrocannabinol |
| Q39361744 | Cannabis use in sickle cell disease: a questionnaire study |
| Q93002580 | Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease? |
| Q38011117 | Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? |
| Q34280435 | Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity |
| Q35613040 | Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor γ in the Induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo |
| Q28071794 | Current Therapeutic Cannabis Controversies and Clinical Trial Design Issues |
| Q47958585 | Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings |
| Q34830551 | Cytokines and anti-cytokine biologicals in autoimmunity: present and future |
| Q91276380 | Decarbonylation: A metabolic pathway of cannabidiol in humans |
| Q44012273 | Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. |
| Q90716407 | Developmental exposure to cannabidiol (CBD) alters longevity and health span of zebrafish (Danio rerio) |
| Q37871350 | Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation |
| Q36653071 | Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes |
| Q37424055 | Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death |
| Q37768965 | Do cannabinoids have a therapeutic role in transplantation? |
| Q92398621 | Dose-Dependent Cannabidiol-Induced Elevation of Intracellular Calcium and Apoptosis in Human Articular Chondrocytes |
| Q37211892 | Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications |
| Q44588994 | Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). |
| Q44892885 | Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats |
| Q34272906 | Effects of cannabidiol (CBD) on regional cerebral blood flow |
| Q44776730 | Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. |
| Q38696763 | Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials |
| Q37250243 | Endocannabinoid signaling in microglial cells |
| Q36257249 | Endocannabinoids and liver disease--review |
| Q39453798 | Endocannabinoids in arthritis: current views and perspective |
| Q38634266 | Expression of Cannabinoid Receptors in Human Osteoarthritic Cartilage: Implications for Future Therapies |
| Q35189004 | Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice |
| Q92104846 | From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome? |
| Q34786818 | From cannabis to cannabinergics: new therapeutic opportunities |
| Q40604593 | Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells |
| Q36077672 | HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid |
| Q52307551 | HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. |
| Q37420471 | Herbal compounds and toxins modulating TRP channels |
| Q90331172 | High-Frequency Medical Cannabis Use Is Associated With Worse Pain Among Individuals With Chronic Pain |
| Q24652736 | Human cannabinoid pharmacokinetics |
| Q93167508 | Immune Responses Regulated by Cannabidiol |
| Q36110873 | Immunoactive cannabinoids: therapeutic prospects for marijuana constituents |
| Q34912871 | Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 |
| Q91979923 | Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey |
| Q34651059 | Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression |
| Q46118910 | Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice |
| Q44850914 | Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies |
| Q27322469 | Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis |
| Q34774970 | Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats |
| Q38185076 | Involvement of the endocannabinoid system in osteoarthritis pain |
| Q26865370 | Is the cardiovascular system a therapeutic target for cannabidiol? |
| Q67496226 | Joint problems arising from lack of repair mechanisms: can cannabinoids help? |
| Q34409573 | Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q55379948 | Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model. |
| Q49609463 | Medical cannabis: A forward vision for the clinician. |
| Q39012168 | Medical cannabis: Another piece in the mosaic of autoimmunity? |
| Q36051068 | Medicinal plants with potential anti-arthritic activity |
| Q34700334 | Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells |
| Q92882814 | Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease |
| Q33636763 | Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. |
| Q28362078 | Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide |
| Q38041231 | Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis |
| Q38299472 | Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids |
| Q35070770 | Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes |
| Q44806587 | News about therapeutic use of Cannabis and endocannabinoid system |
| Q34179008 | Nonpsychotropic cannabinoid receptors regulate microglial cell migration. |
| Q34199882 | Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass |
| Q47156397 | Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. |
| Q44764531 | Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. |
| Q37246019 | Pain and u-shaped dose responses: occurrence, mechanisms, and clinical implications |
| Q91344812 | Paternal activation of CB2 cannabinoid receptor impairs placental and embryonic growth via an epigenetic mechanism |
| Q36965753 | Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells |
| Q34139377 | Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis |
| Q55333056 | Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. |
| Q34185013 | Pharmacokinetics and pharmacodynamics of cannabinoids |
| Q57057886 | Phytochemicals as a potential source for TNF-α inhibitors |
| Q78727774 | Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects |
| Q44506288 | Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils |
| Q81242873 | Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C |
| Q28542740 | Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration |
| Q35035806 | Recent advances in the synthesis of endocannabinoid related ligands |
| Q38073250 | Role of adenosine in diabetic retinopathy. |
| Q33869556 | Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol |
| Q48234381 | Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective |
| Q44301851 | Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid |
| Q24606148 | Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects |
| Q34402827 | Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. |
| Q33947213 | Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis |
| Q34217248 | Taste avoidance and taste aversion: evidence for two different processes |
| Q60300271 | The Anti-Inflammatory Properties of Terpenoids from Cannabis |
| Q34669534 | The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids |
| Q38600704 | The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. |
| Q34509920 | The Pharmacological Basis of Cannabis Therapy for Epilepsy |
| Q52861250 | The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis. |
| Q36784020 | The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis |
| Q46907848 | The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. |
| Q39283731 | The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q47159533 | The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease |
| Q37988405 | The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease |
| Q34181605 | The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells |
| Q62721385 | The pharmacokinetics and the pharmacodynamics of cannabinoids |
| Q37357596 | The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). |
| Q24322122 | The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo |
| Q34910131 | The role of 5-HT1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae). |
| Q36150541 | The safety of cannabinoids for the treatment of multiple sclerosis |
| Q28366593 | The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain |
| Q37997020 | The therapeutic potential of the endocannabinoid system for Alzheimer's disease |
| Q92446152 | The use of cannabis in supportive care and treatment of brain tumor |
| Q45047941 | Therapeutic action of cannabinoids in a murine model of multiple sclerosis. |
| Q35044663 | Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems |
| Q34075110 | Therapeutic potential of anti-inflammatory drugs in focal stroke |
| Q34368715 | Therapeutic potential of cannabinoid medicines |
| Q38974461 | Tissue Engineering of Cartilage; Can Cannabinoids Help? |
| Q40361574 | Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis |
| Q39181416 | Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis |
| Q33897251 | Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder |
| Q38520997 | Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function |
| Q42053693 | Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation |
| Q28540495 | Virtualizing the p-ANAPL library: a step towards drug discovery from African medicinal plants |
| Q91591176 | [rhPDCD5 suppresses pro-inflammatory cytokine secretion and proliferation and induces apoptosis of activated lymphocytes from rats with collagen-induced arthritis] |
Search more.